Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics (NASDAQ: CORT) reported 2025 revenue of $761.4M and net income of $99.7M. Fourth-quarter revenue was $202.1M with Q4 net income of $24.3M (diluted EPS $0.20). Cash and investments totaled $532.4M at year-end. Management provided 2026 revenue guidance of $900M–$1,000M and highlighted key clinical readouts, a July 11, 2026 PDUFA date for relacorilant in platinum-resistant ovarian cancer, and plans for a Phase 3 ALS trial.
Corcept (NASDAQ: CORT) said the U.S. Court of Appeals for the Federal Circuit found that Teva Pharmaceuticals’ marketing of a generic Korlym does not infringe two Corcept patents covering methods for safely co-administering Korlym with CYP3A4 inhibitors.
The ruling affirms a December 2023 District Court verdict. Corcept said it is disappointed and is considering whether to seek further judicial review.
Corcept Therapeutics (NASDAQ: CORT) will report fourth quarter and full‑year 2025 financial results and provide a corporate update on February 24, 2026. A conference call and listen‑only webcast will be held at 5:00 p.m. ET (2:00 p.m. PT), with registration required for dial‑in access and PINs.
A replay will be posted on the Investors / Events tab of Corcept.com after the call.
Corcept (NASDAQ: CORT) reported that its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer met both dual primary endpoints. The combination reduced the risk of death by 35% (HR 0.65; p=0.0004) and extended median overall survival to 16.0 months vs 11.9 months (difference 4.1 months). ROSELLA also showed a 30% reduction in progression risk (HR 0.70; p=0.008). The regimen was well tolerated with similar adverse event profiles versus nab-paclitaxel alone. The NDA is under FDA review with a PDUFA date of July 11, 2026, and an MAA is under EMA review. ROSELLA enrolled 381 patients randomized 1:1 across multiple regions.
Corcept (NASDAQ: CORT) announced that the FDA issued a Complete Response Letter for the NDA for relacorilant as a treatment for hypertension secondary to hypercortisolism. The FDA acknowledged the pivotal GRACE trial met its primary endpoint and found the GRADIENT trial provided confirmatory evidence, but concluded additional evidence of effectiveness is needed before a favorable benefit‑risk assessment can be made.
Corcept said it is surprised and disappointed, remains committed to patients, and will meet with the FDA as soon as possible to discuss next steps.
Corcept Therapeutics (NASDAQ: CORT) reported Q3 2025 revenue of $207.6M (vs. $182.5M in Q3 2024) and net income of $19.7M. Cash and investments were $524.2M at Sept 30, 2025. The company adjusted 2025 revenue guidance to $800–$850M citing prior specialty pharmacy capacity constraints and added a new specialty pharmacy on Oct 1.
Key development milestones include a Dec 30, 2025 PDUFA for relacorilant in hypercortisolism, a Jul 11, 2026 PDUFA for relacorilant in platinum-resistant ovarian cancer, ROSELLA meeting its primary endpoint, upcoming BELLA/BELLA parts and new Phase 2/1b oncology and Phase 3 ALS trials.
Corcept Therapeutics (NASDAQ: CORT) will report third quarter 2025 financial results and provide a corporate update on November 4, 2025. The company will host a conference call on that date at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Participants must register in advance to receive a dial-in number and a unique access PIN; a listen-only webcast will also be available. A replay will be posted on the Investors / Events tab at Corcept.com.
Corcept (NASDAQ: CORT) presented late-breaking Phase 3 ROSELLA data at ESMO 2025 showing relacorilant plus nab-paclitaxel improved outcomes in platinum-resistant ovarian cancer, including patients with prior PARP inhibitor (PARPi) exposure.
Key results: prior PARPi subgroup PFS HR 0.60 (p=0.0035), progressed-on-PARPi subgroup PFS HR 0.56 (p=0.0046) with median PFS 7.36 months. ROSELLA met primary PFS endpoint HR 0.70 (p=0.0076) and interim OS favored the combination HR 0.69 (p=0.0121). Safety in PARPi subgroups was comparable to nab-paclitaxel alone. Corcept also expanded the Phase 2 BELLA trial to three arms; initial BELLA results expected in late 2026.
Corcept (NASDAQ: CORT) submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for relacorilant to treat platinum-resistant ovarian cancer on October 14, 2025.
The submission is based on positive results from the pivotal Phase 3 ROSELLA and Phase 2 trials where relacorilant plus nab-paclitaxel improved progression-free and overall survival versus nab-paclitaxel alone, with no biomarker selection required. Safety in combination was reported as comparable to nab-paclitaxel monotherapy. The U.S. FDA is also reviewing an application, with a PDUFA target action date of July 11, 2026.
Corcept Therapeutics (NASDAQ: CORT) will present new late-breaking data from its pivotal Phase 3 ROSELLA trial at the 2025 ESMO Annual Meeting. The presentation will focus on results of relacorilant plus nab-paclitaxel treatment in platinum-resistant ovarian cancer patients who were previously treated with PARP inhibitors - a group with particularly poor prognosis.
The trial represents a significant international collaboration, involving major oncology research groups including GOG-F, ENGOT, APGOT, LACOG, and ANZGOG. The presentation (LBA45) is scheduled for October 19, 2025, at 10:15 AM CEST during the gynaecological cancers mini oral session.